Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
Sponsor: Novartis Pharmaceuticals
Terminated
Company decision
Other terminated trials from Novartis Pharmaceuticals
Other Metastatic Melanoma trials with similar outcome
A observational or N/A phase clinical study on Metastatic Melanoma, this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 3 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jun 2023 — Jul 2024 [monthly]
Terminated
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .